← Eichor
Condition: Glioblastoma Multiform Grade Iv Astrocytoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Glioblastoma Multiform Grade Iv Astrocytoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Phase 1 · 1 location(s) · Plus Therapeutics · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Phase 1/Phase 2 · 3 location(s) · Plus Therapeutics · NCT01906385Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastom
Phase 3 · 4 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT071007305G-EMERALD: Amivantamab in Malignant Brain Tumours
Phase 1 · 2 location(s) · Institute of Cancer Research, United Kingdom · NCT06632236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.